The TOR1AIP1 antibody targets the Torsin-1A-interacting protein 1 (TOR1AIP1), also known as lamina-associated polypeptide 1 (LAP1), a nuclear envelope protein encoded by the TOR1AIP1 gene. LAP1 interacts with TorsinA, a AAA+ ATPase linked to early-onset dystonia (DYT1) when mutated. This interaction is critical for maintaining nuclear envelope structure, regulating endoplasmic reticulum-nuclear envelope communication, and influencing cellular processes like chromatin organization and mechanotransduction. TOR1AIP1 mutations are associated with severe musculoskeletal disorders, including congenital muscular dystrophy with nuclear envelopathies, highlighting its role in muscle and neuronal homeostasis. Antibodies against TOR1AIP1 are essential tools for studying its expression, localization, and function in disease models. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding research into nuclear envelope dynamics, TorsinA-related pathologies, and mechanisms underlying muscle degeneration. Recent studies also explore LAP1's involvement in cellular stress responses and viral infection pathways. Validated TOR1AIP1 antibodies help dissect molecular pathways in genetic disorders and potential therapeutic targets, bridging gaps between basic research and clinical understanding of nuclear envelopathies.